🔥🐔 BizChicken 🐔🔥
Companies Similar to Ionis Pharmaceuticals, Inc.
Sign Up Today!
Sign up for BizChicken and discover more about the corporations around you.
Bio-Path Holdings, Inc.
DNAbilize
Bio-Path Holdings, Inc. is a clinical and preclinical stage oncology focused RNAi nano particle drug development company, developing products based on the DNAbilize technology. The company is advancing its lead drug candidate, prexigebersen, for the treatment of AML and myelodysplastic syndrome.
Symbol: BPTH
Recent Price: $1.17
Industry: Biotechnology
CEO: Mr. Peter H. Nielsen MBA
Sector: Healthcare
Employees: 10
Address: 4710 Bellaire Boulevard, Bellaire, TX 77401
Phone: 832 742 1357
Leadership
- Peter Nielsen, Chief Executive Officer, Chief Financial Officer
- Ana Tari Ashizawa, PhD, MBA, Senior Vice President of Research, Development & Clinical Design
- Anthony Price, MBA, Senior Vice President of Finance, Accounting & Administration
- Michael Hickey, MBA, Vice President of Clinical Operations
- Michael Roberts, Director of Manufacturing Planning & Engineering
- Chairman of the Board,
- President,
- Heath Cleaver, Director
- Paul Aubert, Director
- Douglas P. Morris, Director
- Aline Sherwood, Director
Last updated: 2024-12-31
Cyclerion Therapeutics, Inc.
CY6463
Cyclerion Therapeutics is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing medicines for serious CNS diseases, with products like CY6463 for mitochondrial encephalomyopathy and Alzheimer's disease.
Symbol: CYCN
Recent Price: $3.45
Industry: Biotechnology
CEO: Dr. Regina Graul Ph.D.
Sector: Healthcare
Employees: 1
Address: 245 First Street, Cambridge, MA 02142
Phone: 857 327 8778
Last updated: 2024-12-31
Inhibrx Biosciences, Inc.
Therapeutic Candidates (INBRX-109, INBRX-106)
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops biologic therapeutics for life-threatening conditions, with therapeutic candidates in phase 2 clinical trials targeting various cancers.
Symbol: INBX
Recent Price: $15.14
Industry: Biotechnology
CEO: Mr. Mark Paul Lappe
Sector: Healthcare
Employees: 166
Address: 11025 North Torrey Pines Road, La Jolla, CA 92037
Phone: 858-795-4220
Last updated: 2024-12-31
Reneo Pharmaceuticals, Inc.
REN001
Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on developing therapies for patients with rare genetic mitochondrial diseases. Its primary product, REN001, is a selective peroxisome proliferator-activated receptor delta agonist currently in clinical trials.
About | About | About | Management | Directors | Contact | Contact | Careers | Careers | About | About | About
Symbol: RPHM
Recent Price: $18.20
Industry: Biotechnology
CEO: Mr. Gregory J. Flesher
Sector: Healthcare
Employees: 8
Address: 18575 Jamboree Road, Irvine, CA 92612
Phone: 619 733 3852
Last updated: 2024-12-31
Sarepta Therapeutics, Inc.
EXONDYS 51, VYONDYS 53, AMONDYS 45, SRP-5051, SRP-9001, SRP-9003
Sarepta Therapeutics, Inc. is a biopharmaceutical company focused on developing RNA-targeted therapeutics and gene therapies for rare diseases, including treatments for Duchenne muscular dystrophy.
Contact | About | Leadership | About | About | About | Locations | About | About | About | About
Symbol: SRPT
Recent Price: $121.19
Industry: Biotechnology
CEO: Mr. Douglas S. Ingram Esq.
Sector: Healthcare
Employees: 1314
Address: 215 First Street, Cambridge, MA 02142
Phone: 617 274 4000
Leadership
- Douglas S. Ingram, President and Chief Executive Officer
- Bilal Arif, Executive Vice President, Chief Technical Operations Officer
- Diane Berry, PhD, Executive Vice President, Chief Global Policy & Advocacy Officer
- Ryan E. Brown, JD, Executive Vice President, Chief General Counsel
- Ian M. Estepan, Executive Vice President, Chief Financial Officer
- Dallan Murray, Executive Vice President, Chief Customer Officer
- Alison Nasisi, Executive Vice President, Chief People Officer
- Louise R. Rodino-Klapac, PhD, Executive Vice President, Head of R&D, Chief Scientific Officer
- Will Tilton, Senior Vice President, Head of Strategy, Chief of Staff
- M. Kathleen Behrens, PhD, Chairwoman
- Richard J. Barry,
- Kathryn Boor, PhD,
- Michael Chambers,
- Deirdre Connelly,
- Stephen L. Mayo, PhD,
- Claude Nicaise, MD,
- Hans Wigzell, MD, PhD,
- John C. Martin, PhD (In Memoriam),
- Annemieke Aartsma-Rus, PhD,
- Carsten Bönnemann, MD,
- Joy Cavagnaro, PhD, DABT, Fellow ATS,
- Kay Davies, PhD, DBE FMedSci FRS,
- Steven Gray, PhD,
- Angela J. Russell, DPhil,
Last updated: 2024-12-31
Aileron Therapeutics, Inc.
ALRN-6924
Aileron Therapeutics, Inc. is a clinical stage oncology company developing ALRN-6924 for various cancer treatments, with multiple clinical trials in progress.
Symbol: ALRN
Recent Price: $2.32
Industry: Biotechnology
CEO: Dr. James Brian Windsor Ph.D.
Sector: Healthcare
Employees: 15
Address: 285 Summer Street, Boston, MA 02210
Phone: 617 995 0900
Last updated: 2024-12-31
Celcuity Inc.
CELsignia diagnostic platform
Celcuity Inc., a biotechnology company, develops targeted therapies for cancer patients in the US, including the CELsignia diagnostic platform and Gedatolisib drug candidate.
Symbol: CELC
Recent Price: $13.13
Industry: Biotechnology
CEO: Mr. Brian F. Sullivan
Sector: Healthcare
Employees: 55
Address: 16305–36th Avenue North, Minneapolis, MN 55446
Phone: 763 392 0767
Leadership
- Brian Sullivan, CEO and Co-founder
- Lance Laing, PhD, Chief Science Officer and Co-founder
- Vicky Hahne, CFO
- Igor Gorbatchevsky, MD, Chief Medical Officer
- Eldon Mayer, Chief Commercial Officer
- Brent Eilefson, General Counsel
- Bernhard Lampert, PhD, VP of Pharmaceutical Development
- Nadene Zack, VP Clinical Operations
- Sunni Miller, VP of Regulatory Affairs
- David Bridge, VP of Quality Assurance and Process Development
- William Strickland, PharmD, VP of Medical Affairs
- Fred Kerwood, VP of Program Management
- Charlotte Moser, MD, PhD, SVP of Clinical Development
- John R. MacDonald, PhD, SVP of R&D
- Lance Laing, PhD, Chief Science Officer and Co-Founder
- Richard Buller, MD, PhD, Director
- David F. Dalvey, Director
- Leo Furcht, MD, Director
- Polly Murphy, DVM, PhD, Director
- Richard J. Nigon, Director
Last updated: 2024-12-31
iTeos Therapeutics, Inc.
inupadenant, EOS-448
Iteos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of immuno-oncology therapeutics. Their product pipeline includes inupadenant and EOS-448, which are in various phases of clinical trials.
About | Leadership | Directors | About | About | About | About | Contact | Careers | About | About | About | About | About | About
Symbol: ITOS
Recent Price: $7.29
Industry: Biotechnology
CEO: Dr. Michel Detheux Ph.D.
Sector: Healthcare
Employees: 157
Address: 321 Arsenal Street, Cambridge, MA 02472-5710
Phone: 339 217 0161
Leadership
- Michel DETHEUX, President, Chief Executive Officer
- Matt CALL, Chief Operating Officer
- Matthew GALL, Chief Financial Officer
- Yvonne MCGRATH, Chief Scientific Officer
- David Feltquate, Chief Medical Officer
- Philippe BRANTEGEM, Executive Vice President of Human Resources
- Adi OSOVSKY, Executive Vice President of Legal
- David HALLAL, Chair of the Board
- Aaron DAVIS,
- Jill DESIMONE,
- David LEE,
- Tim VAN HAUWERMEIREN,
- Tony HO,
- Robert IANNONE,
- Ann RHOADS,
Last updated: 2024-12-31
Moderna, Inc.
messenger RNA therapeutics and vaccines
Moderna, Inc. is a biotechnology company specializing in the discovery, development, and commercialization of messenger RNA therapeutics and vaccines for various diseases including infectious diseases and cancer. It operates globally with a range of vaccines targeting respiratory, latent, and public health viruses.
Vision/Values | Contact | Careers | Careers | Careers | Careers | About | Careers | About | About | About | About | About | About | About | About | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Awards | Careers | Careers | Careers | Careers | Careers | Careers | About | About | About | About | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Awards | Awards | Awards | Awards | Awards | Awards | Awards | Awards | Awards | Awards | Awards | Awards | Awards | Awards | Awards | Awards | Awards | Awards | Awards | Awards | Awards | Awards | Careers | Careers | About | About | About | About | About | News | About
Symbol: MRNA
Recent Price: $39.38
Industry: Biotechnology
CEO: Mr. Stephane Bancel
Sector: Healthcare
Employees: 5600
Address: 200 Technology Square, Cambridge, MA 02139
Phone: 617 714 6500
Last updated: 2024-12-31
Intellia Therapeutics, Inc.
NTLA-2001, NTLA-2002, NTLA-5001
Intellia Therapeutics, Inc. is a genome editing company specializing in developing therapeutics, with a focus on in vivo and ex vivo programs, including treatments for transthyretin amyloidosis, hereditary angioedema, and acute myeloid leukemia. The company also develops engineered cell therapies and offers CRISPR/Cas9 tools.
News | About | About | Contact | Careers | Culture | DEI | Careers | Careers | Careers | Culture | Jobs | Jobs | Careers | Careers | Careers | Jobs | About | About | About
Symbol: NTLA
Recent Price: $11.41
Industry: Biotechnology
CEO: Dr. John M. Leonard M.D.
Sector: Healthcare
Employees: 526
Address: 40 Erie Street, Cambridge, MA 02139
Phone: 857 285 6200
Last updated: 2024-12-31
Phio Pharmaceuticals Corp.
INTASYL therapeutic platform
Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics using its INTASYL therapeutic platform to target tumor and immune cells by regulating genes of the immune system, focusing on products like PH-762, PH-894, and PH-804 for enhancing cancer immunotherapies in adoptive cell transfer.
Symbol: PHIO
Recent Price: $1.90
Industry: Biotechnology
CEO: Mr. Robert J. Bitterman
Sector: Healthcare
Employees: 8
Address: 257 Simarano Drive, Marlborough, MA 01752
Phone: 508 767 3861
Last updated: 2024-12-31
Pliant Therapeutics, Inc.
PLN-74809
Pliant Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on discovering, developing, and commercializing novel therapies for the treatment of fibrosis and related diseases. Their lead product candidate, PLN-74809, is currently in Phase 2a trials.
Symbol: PLRX
Recent Price: $12.79
Industry: Biotechnology
CEO: Dr. Bernard Coulie M.B.A., M.D., Ph.D.
Sector: Healthcare
Employees: 166
Address: 260 Littlefield Avenue, South San Francisco, CA 94080
Phone: 650 481 6770
Last updated: 2024-12-31
PTC Therapeutics, Inc.
Translarna, Emflaza, Tegsedi, Waylivra, Evrysdi
PTC Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering, developing, and commercializing medicines for patients with rare disorders. The company offers a portfolio of products including treatments for Duchenne muscular dystrophy, rare diseases, and spinal muscular atrophy.
About | History | Leadership | About | Contact | Careers | Careers | Jobs | About | About | About | About
Symbol: PTCT
Recent Price: $45.77
Industry: Biotechnology
CEO: Dr. Matthew B. Klein F.A.C.S., M.D., M.S.
Sector: Healthcare
Employees: 988
Address: 100 Corporate Court, South Plainfield, NJ 07080
Phone: 908 222 7000
Leadership
- Matthew B. Klein, M.D., M.S., F.A.C.S., CEO, PTC Therapeutics, Inc.
- Neil Almstead, Ph.D., Chief Technical Operations Officer
- John Baird, Ph.D., Chief of Staff to the CEO
- Mark E. Boulding, Executive Vice President and Chief Legal Officer
- Lee Golden, M.D., Chief Medical Officer
- Pierre Gravier, Chief Financial Officer
- Mary Frances Harmon, Senior Vice President, Corporate and Patient Relations
- Linda Montella-Carter, Senior Vice President and Chief Information Officer
- Eric Pauwels, Chief Business Officer
- Hege Sollie-Zetlmayer, Chief Human Resources Officer
- Christine Utter, Senior Vice President, Chief Accounting Officer and Head of People Services
- Michael Schmertzler, Chairman
- William F. Bell, Jr., Managing Director and Head of Healthcare Services Practice, L.E.K. Consulting
- Allan Jacobson, Ph.D., University of Massachusetts Chan Medical School
- Stephanie S. Okey, M.S., Former SVP, Head of North America, Rare Disease – Genzyme
- Emma Reeve, Independent Board Director
- Mary Smith, The VENG Group
- David P. Southwell, Former CEO, TScan Therapeutics
- Glenn D. Steele, Jr., M.D., Ph.D., Chairman, GSteele Health Solutions
- Alethia Young, Chief Financial Officer, Bicycle Therapeutics
- Jerome B. Zeldis, M.D., Ph.D., Independent Board Director
Last updated: 2024-12-31
Rocket Pharmaceuticals, Inc.
Gene Therapies
Rocket Pharmaceuticals, Inc. is a biotechnology company focused on developing gene therapies for rare and devastating diseases, with multiple clinical-stage programs targeting disorders such as fanconi anemia, leukocyte adhesion deficiency-I, pyruvate kinase deficiency, and Danon disease.
Symbol: RCKT
Recent Price: $12.03
Industry: Biotechnology
CEO: Dr. Gaurav D. Shah M.D.
Sector: Healthcare
Employees: 268
Address: 9 Cedarbrook Drive, Cranbury, NJ 08512
Phone: 609 659 8001
Last updated: 2024-12-31
Regulus Therapeutics Inc.
RG-012 and RGLS8429
Regulus Therapeutics Inc., based in San Diego, focuses on discovering and developing drugs targeting micro RNAs for treating various diseases.
Symbol: RGLS
Recent Price: $1.50
Industry: Biotechnology
CEO: Mr. Joseph P. Hagan M.B.A.
Sector: Healthcare
Employees: 30
Address: 4224 Campus Point Court, San Diego, CA 92121
Phone: 858 202 6300
Last updated: 2024-12-31
Relay Therapeutics, Inc.
RLY-4008, RLY-2608, RLY-1971
Relay Therapeutics, Inc. is a clinical-stage company that focuses on precision medicine in oncology and genetic diseases by transforming the drug discovery process. Their leading products include small molecule inhibitors for advanced cancer treatment.
Symbol: RLAY
Recent Price: $4.18
Industry: Biotechnology
CEO: Dr. Sanjiv K. Patel M.A., M.B.A., M.D., MBBS
Sector: Healthcare
Employees: 323
Address: 399 Binney Street, Cambridge, MA 02139
Phone: 617 370 8837
Last updated: 2024-12-31
TRACON Pharmaceuticals, Inc.
therapeutics for cancer
TRACON Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing cancer therapeutics, including clinical stage products like envafolimab, YH001, TRC102, and TJ004309, with collaboration agreements with various biopharmaceutical companies.
Symbol: TCON
Recent Price: $0.03
Industry: Biotechnology
CEO: Mr. Craig R. Jalbert CIRA
Sector: Healthcare
Employees: 17
Address: 4350 La Jolla Village Drive, San Diego, CA 92122
Phone: 858 550 0780
Last updated: 2024-12-31
Arcturus Therapeutics Holdings Inc.
RNA medicines
Arcturus Therapeutics Holdings Inc. focuses on developing vaccines for infectious and rare diseases, including programs for cystic fibrosis and ornithine transcarbamylase deficiency. The company collaborates with various partners for vaccine and therapeutic development.
Symbol: ARCT
Recent Price: $16.58
Industry: Biotechnology
CEO: Mr. Joseph E. Payne M.Sc.
Sector: Healthcare
Employees: 180
Address: 10628 Science Center Drive, San Diego, CA 92121
Phone: 858 900 2660
Last updated: 2024-12-31
Ionis Pharmaceuticals, Inc.
RNA-targeted therapeutics
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States, offering treatments like SPINRAZA, TEGSEDI, and WAYLIVRA, while developing medicines in phase 3 studies for various indications including TTR amyloidosis, severe hypertriglyceridemia, and amyotrophic lateral sclerosis.
About | About | About | DEI | DEI | DEI | DEI | Contact | Contact | Careers | Careers | Careers | Careers | Careers | Careers | About | About | News | About | About | ESG | DEI | DEI | About | About | About | Management | About | About | About | About | About | About | About | About | About | About | Careers | Careers | Careers | Careers | Careers | ESG | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | About | About | About | About | About | About | About | Jobs | About | About
Symbol: IONS
Recent Price: $34.92
Industry: Biotechnology
CEO: Dr. Brett P. Monia Ph.D.
Sector: Healthcare
Employees: 927
Address: 2855 Gazelle Court, Carlsbad, CA 92010
Phone: 760 931 9200
Last updated: 2024-12-31
Tango Therapeutics, Inc.
TNG908
Tango Therapeutics, Inc. is a biotechnology company focused on discovering and developing drugs for cancer treatment, with a lead program TNG908 targeting cancers with methylthioadenosine phosphorylase deletions. The company also works on therapies for BRCA1/2-mutant and STK11-mutant cancers and collaborates with Gilead Sciences, Inc.
Symbol: TNGX
Recent Price: $3.10
Industry: Biotechnology
CEO: Dr. Barbara L. Weber M.D.
Sector: Healthcare
Employees: 140
Address: 100 Binney Street, Cambridge, MA 02142
Phone: 857 320 4900
Last updated: 2024-12-31